Suprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial.
Pauline T MerrillChristopher R HenryQuan Dong NguyenAshvini ReddyBarry KapikThomas A CiullaPublished in: Ocular immunology and inflammation (2021)
A clinically meaningful benefit of CLS-TA was noted in UME patients, regardless of concurrent ST usage.Abbreviation and AcronymsCST = central subfield thickness; BCVA = best corrected visual acuity; ME = macular edemaI; IVT = intravitreal; AE = adverse event; FA = fluocinolone acetonide; SD-OCT = spectral-domain optical coherence tomography; NIU = noninfectious uveitis; SAE = serious adverse event; TEAE = treatment emergent adverse event; ITT = intent to treat; CI = confidence interval.
Keyphrases
- optical coherence tomography
- diabetic retinopathy
- clinical trial
- end stage renal disease
- optic nerve
- ejection fraction
- chronic kidney disease
- prognostic factors
- squamous cell carcinoma
- emergency department
- vascular endothelial growth factor
- open label
- randomized controlled trial
- juvenile idiopathic arthritis
- patient reported outcomes
- stem cells
- age related macular degeneration
- magnetic resonance
- rheumatoid arthritis
- locally advanced
- mesenchymal stem cells
- electronic health record